Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now full pipeline small index

Juvenile Idiopathic Arthritis: full-pipeline trial registry

3 of 9 indexed Juvenile Idiopathic Arthritis trials are currently recruiting.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Juvenile Idiopathic Arthritis: 9 US clinical trials tracked, 3 recruiting.

Juvenile Idiopathic Arthritis is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is AbbVie, running 2 of these trials.

Enrollment posture brief

Registry condition juvenile-idiopathic-arthritis

OPEN 3 | RECR 33% | LATE 3 | EARLY 2 | RANK #1916 | SPON 2

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Juvenile Idiopathic Arth (th…33%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Juvenile Idiopathic Arthritis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Juvenile Idiopathic Arthritis is recruiting below its size-band peers.

    3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Juvenile Idiopathic Arthritis research.

    AbbVie accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Juvenile Idiopathic Arthritis enrolment sits around 90 participants.

    Median target enrolment is 90 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Juvenile Idiopathic Arthritis splits between interventional and observational designs.

    6 interventional and 3 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21Phase 31Phase 42

Open and recent trials

9 total, page 1 of 1

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 1
Phase 4 2

Named interventions

Most-linked intervention names on Juvenile Idiopathic Arthritis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Tocilizumab Drug
2 trials
methotrexate - etanercept - prednisolone arm Drug
1 trials
800 mg ibuprofen/26.6 mg famotidine Drug
1 trials
adalimumab Biological
1 trials
methotrexate Drug
1 trials
Cold pain tolerance (duration in seconds) Behavioral
1 trials
Pressure pain thresholds (measured in kilopascal) Behavioral
1 trials
Tofacitinib Drug
1 trials

US sites by state

Facility locations filed on Juvenile Idiopathic Arthritis trials. A trial with sites in several states counts in each.

Ohio 4 trials
New Jersey 4 trials
North Carolina 4 trials
Arkansas 4 trials
New York 3 trials
Massachusetts 3 trials
California 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Juvenile Idiopathic Arthritis page

9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Juvenile Idiopathic Arthritis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • AbbVie sponsors the most Juvenile Idiopathic Arthritis trials on record, review their full trial history before evaluating a specific study. See AbbVie's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Juvenile Idiopathic Arthritis condition card totals 9 registered trials; most-linked intervention Tocilizumab; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.